{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:32:07Z","timestamp":1792873927256,"version":"4.5.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Since December 2019, the SARS-CoV-2 has erupted on a large scale worldwide and spread rapidly. Passive immunization of antibody-related molecules provides opportunities for prevention and treatment of high-risk patients and children. Nanobodies (Nbs) have many strong physical and chemical properties. They can be atomized, administered by inhalation, and can be directly applied to the infected site, with fast onset, high local drug concentration\/high bioavailability, and high patient compliance (no needles). It has very attractive potential in the treatment of respiratory viruses. Rapid and low-cost development of Nbs targeting SARS-CoV-2 can quickly be achieved. Nbs against SARS-CoV-2 mutant strains also can be utilized quickly to prevent the virus from escaping. It provides important technical supports for the treatment of the SARS-CoV-2 and has the potential to become an essential medicine in the toolbox against the SARS-CoV-2.<\/jats:p>","DOI":"10.3389\/fimmu.2021.690742","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T07:55:38Z","timestamp":1622188538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Prospects of Neutralizing Nanobodies Against SARS-CoV-2"],"prefix":"10.3389","volume":"12","author":[{"given":"Fangfang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus From Patients With Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","article-title":"A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0365-7","article-title":"Passive Antibody Therapy in Covid-19","volume":"20","author":"Abraham","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults","volume":"384","author":"Libster","year":"2021","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human Neutralizing Antibodies Elicited by Sars-Cov-2 Infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6","article-title":"and Crowe JE, Jr. Potently Neutralizing and Protective Human Antibodies Against Sars-Cov-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5902","article-title":"Potent Neutralizing Antibodies From Covid-19 Patients Define Multiple Targets of Vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent Human Antibodies Protect Against Sars-Cov-2 Challenge Via Multiple Mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent Antibody Responses to Sars-Cov-2 in Convalescent Individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7520","article-title":"Isolation of Potent Sars-Cov-2 Neutralizing Antibodies and Protection From Disease in a Small Animal Model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849","article-title":"Sars-Cov-2 Neutralizing Antibody Ly-Cov555 in Outpatients With Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"Regn-Cov2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling Medicines: Delivering Drugs to the Body Through the Lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0321-6","article-title":"The Potential Danger of Suboptimal Antibody Responses in Covid-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0732-8","article-title":"Covid-19 Antibodies on Trial","volume":"38","author":"DeFrancesco","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(01)79006-2","article-title":"Functional Heavy-Chain Antibodies in Camelidae","volume":"79","author":"Nguyen","year":"2001","journal-title":"Adv Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/7.9.1129","article-title":"Sequence and Structure of Vh Domain From Naturally Occurring Camel Heavy Chain Immunoglobulins Lacking Light Chains","volume":"7","author":"Muyldermans","year":"1994","journal-title":"Protein Engineering"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(97)00146-6","article-title":"Comparison of Llama Vh Sequences From Conventional and Heavy Chain Antibodies","volume":"34","author":"Vu","year":"1997","journal-title":"Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0167-4838(99)00030-8","article-title":"Comparison of Physical Chemical Properties of Llama Vhh Antibody Fragments and Mouse Monoclonal Antibodies","volume":"1431","author":"van der Linden","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1110\/ps.34602","article-title":"Single-Domain Antibody Fragments With High Conformational Stability","volume":"11","author":"Dumoulin","year":"2002","journal-title":"Protein Sci Publ Protein Society"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.04.050","article-title":"Antigen Binding and Solubility Effects Upon the Veneering of a Camel Vhh in Framework-2 to Mimic a Vh","volume":"350","author":"Conrath","year":"2005","journal-title":"J Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1038\/s41598-018-26338-z","article-title":"The Structural Basis of Nanobody Unfolding Reversibility and Thermoresistance","volume":"8","author":"Kunz","year":"2018","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-017-8644-3","article-title":"Expression of Single-Domain Antibody in Different Systems","volume":"102","author":"Liu","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"105645","DOI":"10.1016\/j.pep.2020.105645","article-title":"Recombinant Expression of Nanobodies and Nanobody-Derived Immunoreagents","volume":"172","author":"de Marco","year":"2020","journal-title":"Protein Expression Purification"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.7b00470","article-title":"Evaluation of Nanobody Conjugates and Protein Fusions as Bioanalytical Reagents","volume":"89","author":"Bruce","year":"2017","journal-title":"Analytical Chem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sbi.2015.01.001","article-title":"Camelid Nanobodies: Killing Two Birds With One Stone","volume":"32","author":"Desmyter","year":"2015","journal-title":"Curr Opin Struct Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: Outstanding Features for Diagnostic and Therapeutic Applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Analytical bioanalytical Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-Based Car T Cells That Target the Tumor Microenvironment Inhibit the Growth of Solid Tumors in Immunocompetent Mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/HAB-190390","article-title":"Nanobodies: The \u201cMagic Bullets\u201d in Therapeutics, Drug Delivery and Diagnostics","volume":"28","author":"Mir","year":"2020","journal-title":"Hum Antibodies"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Jovcevska","year":"2020","journal-title":"BioDrugs Clin Immunotherapeutics Biopharmaceuticals Gene Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.drudis.2018.06.003","article-title":"Therapeutic Application of Antibody Fragments in Autoimmune Diseases: Current State and Prospects","volume":"23","author":"Fernandes","year":"2018","journal-title":"Drug Discovery Today"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2014.03.001","article-title":"Nanobody-Based Products as Research and Diagnostic Tools","volume":"32","author":"De Meyer","year":"2014","journal-title":"Trends Biotechnol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e95263","DOI":"10.1371\/journal.pone.0095263","article-title":"Development of Vhh Antibodies Against Dengue Virus Type 2 Ns1 and Comparison With Monoclonal Antibodies for Use in Immunological Diagnosis","volume":"9","author":"Fatima","year":"2014","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.016063-0","article-title":"Production, Characterization and in Vitro Testing of Hbcag-Specific Vhh Intrabodies","volume":"91","author":"Serruys","year":"2010","journal-title":"J Gen Virology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26430","article-title":"An Alpaca Nanobody Inhibits Hepatitis C Virus Entry and Cell-to-Cell Transmission","volume":"58","author":"Tarr","year":"2013","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.05.012","article-title":"In Vitro Antiviral Activity of Single Domain Antibody Fragments Against Poliovirus","volume":"87","author":"Thys","year":"2010","journal-title":"Antiviral Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1006636","DOI":"10.1371\/journal.ppat.1006636","article-title":"Nanobodies Targeting Norovirus Capsid Reveal Functional Epitopes and Potential Mechanisms of Neutralization","volume":"13","author":"Koromyslova","year":"2017","journal-title":"PloS Pathogens"},{"key":"B38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12934-017-0837-z","article-title":"Selection, Characterization, and Thermal Stabilization of Llama Single Domain Antibodies Towards Ebola Virus Glycoprotein","volume":"16","author":"Liu","year":"2017","journal-title":"Microbial Cell Factories"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012865107","article-title":"Cxcr4 Nanobodies (Vhh-Based Single Variable Domains) Potently Inhibit Chemotaxis and Hiv-1 Replication and Mobilize Stem Cells","volume":"107","author":"Jahnichen","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00189","article-title":"Unravelling the Molecular Basis of High Affinity Nanobodies Against Hiv P24: in Vitro Functional, Structural, and in Silico Insights","volume":"3","author":"Gray","year":"2017","journal-title":"ACS Infect Diseases"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0004902","DOI":"10.1371\/journal.pntd.0004902","article-title":"Post-Exposure Treatment With Anti-Rabies Vhh and Vaccine Significantly Improves Protection of Mice From Lethal Rabies Infection","volume":"10","author":"Terryn","year":"2016","journal-title":"PloS neglected Trop Diseases"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0162351","DOI":"10.1371\/journal.pone.0162351","article-title":"Anti-Vp6 Vhh: An Experimental Treatment for Rotavirus a-Associated Disease","volume":"11","author":"Maffey","year":"2016","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.antiviral.2011.09.002","article-title":"Nanobodies(R): New Ammunition to Battle Viruses","volume":"92","author":"Vanlandschoot","year":"2011","journal-title":"Antiviral Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and Characterization of Alx-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection","volume":"60","author":"Detalle","year":"2016","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"eaas9667","DOI":"10.1126\/sciadv.aas9667","article-title":"Chimeric Camel\/Human Heavy-Chain Antibodies Protect Against Mers-Cov Infection","volume":"4","author":"Stalin Raj","year":"2018","journal-title":"Sci Advances"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e103294","DOI":"10.1371\/journal.pone.0103294","article-title":"The Breadth of Cross Sub-Type Neutralisation Activity of a Single Domain Antibody to Influenza Hemagglutinin Can Be Increased by Antibody Valency","volume":"9","author":"Hufton","year":"2014","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq168","article-title":"Nanobodies With in Vitro Neutralizing Activity Protect Mice Against H5n1 Influenza Virus Infection","volume":"203","author":"Ibanez","year":"2011","journal-title":"J Infect Diseases"},{"key":"B48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal Protection Against Influenza Infection by a Multidomain Antibody to Influenza Hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","article-title":"Nebulised Alx-0171 for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Hospitalised Children: A Double-Blind, Randomised, Placebo-Controlled, Phase 2b Trial","volume":"9","author":"Cunningham","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0359-5","article-title":"Dissecting Antibody-Mediated Protection Against Sars-Cov-2","volume":"20","author":"Zohar","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0577-1","article-title":"Implications of Antibody-Dependent Enhancement of Infection for Sars-Cov-2 Countermeasures","volume":"38","author":"Eroshenko","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01531","article-title":"Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, Sars-Cov-2","volume":"11","author":"Konwarh","year":"2020","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1038\/s41467-020-17371-6","article-title":"Cryo-Em Analysis of the Post-Fusion Structure of the Sars-Cov Spike Glycoprotein","volume":"11","author":"Fan","year":"2020","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.11.944462","article-title":"Cryo-Em Structure of the 2019-Ncov Spike in the Prefusion Conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"BioRxiv Preprint Server Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1007236","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-Em Structure of the Sars Coronavirus Spike Glycoprotein in Complex With Its Host Cell Receptor Ace2","volume":"14","author":"Song","year":"2018","journal-title":"PloS Pathogens"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, Function, and Antigenicity of the Sars-Cov-2 Spike Glycoprotein","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5881","article-title":"Structural Basis for Neutralization of Sars-Cov-2 and Sars-Cov by a Potent Therapeutic Antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1101\/2020.05.28.121533","article-title":"Structures of Human Antibodies Bound to Sars-Cov-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe3255","article-title":"An Ultrapotent Synthetic Nanobody Neutralizes Sars-Cov-2 by Stabilizing Inactive Spike","volume":"370","author":"Schoof","year":"2020","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6230","article-title":"Structure-Guided Multivalent Nanobodies Block Sars-Cov-2 Infection and Suppress Mutational Escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.23.432569","article-title":"Inhalable Nanobody (Pin-21) Prevents and Treats Sars-Cov-2 Infections in Syrian Hamsters At Ultra-Low Doses","author":"Nambulli","year":"2021","journal-title":"BioRxiv Preprint Server Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.24.264333","article-title":"Versatile and Multivalent Nanobodies Efficiently Neutralize Sars-Cov-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1038\/s41467-020-18174-5","article-title":"An Alpaca Nanobody Neutralizes Sars-Cov-2 by Blocking Receptor Interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.60","article-title":"A potent neutralizing nanobody against sars-cov-2 with inhaled delivery potential","volume-title":"Med Comm","author":"Gai","year":"2021"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","article-title":"Gisaid: Global Initiative on Sharing All Influenza Data - From Vision to Reality","volume":"22","author":"Shu","year":"2017","journal-title":"Euro surveillance Bull Europeen sur les maladies transmissibles = Eur Communicable Dis Bulletin"},{"key":"B67","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s42003-021-01754-6","article-title":"Analysis of Sars-Cov-2 Mutations in the United States Suggests Presence of Four Substrains and Novel Variants","volume":"4","author":"Wang","year":"2021","journal-title":"Commun Biol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molimm.2018.02.012","article-title":"Recent Advances in the Selection and Identification of Antigen-Specific Nanobodies","volume":"96","author":"Liu","year":"2018","journal-title":"Mol Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing Nanobodies Bind Sars-Cov-2 Spike Rbd and Block Interaction With Ace2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1039\/C8CS00523K","article-title":"Third Generation Antibody Discovery Methods: in Silico Rational Design","volume":"47","author":"Sormanni","year":"2018","journal-title":"Chem Soc Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.16228","article-title":"Nali-H1: A Universal Synthetic Library of Humanized Nanobodies Providing Highly Functional Antibodies and Intrabodies","volume":"5","author":"Moutel","year":"2016","journal-title":"eLife"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-018-0028-6","article-title":"Yeast Surface Display Platform for Rapid Discovery of Conformationally Selective Nanobodies","volume":"25","author":"McMahon","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.23.165415","article-title":"Selection, Biophysical and Structural Analysis of Synthetic Nanobodies That Effectively Neutralize SARS-Cov-2. Preprint At","author":"T\u00e2nia","year":"2021","journal-title":"bioRxiv"},{"key":"B74","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of Human Single-Domain Antibodies Against Sars-Cov-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.16.045419","article-title":"Sybodies Targeting the SARS-Cov-2 Receptor-Binding Domain. Preprint At","author":"Walter","year":"2020","journal-title":"bioRxiv"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2101918118","article-title":"Nanobody Cocktails Potently Neutralize Sars-Cov-2 D614g N501y Variant and Protect Mice","volume":"118","author":"Pymm","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bth053","article-title":"Large-Scale Co-Evolution Analysis of Protein Structural Interlogues Using the Global Protein Structural Interactome Map (Psimap)","volume":"20","author":"Kim","year":"2004","journal-title":"Bioinformatics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03348-4","article-title":"\u2018It Will Change Everything\u2019: Deepmind\u2019s Ai Makes Gigantic Leap in Solving Protein Structures","volume":"588","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/prot.25834","article-title":"Protein Structure Prediction Using Multiple Deep Neural Networks in the 13th Critical Assessment of Protein Structure Prediction (Casp13)","volume":"87","author":"Senior","year":"2019","journal-title":"Proteins"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan0693","article-title":"Global Analysis of Protein Folding Using Massively Parallel Design, Synthesis, and Testing","volume":"357","author":"Rocklin","year":"2017","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/nature23912","article-title":"Massively Parallel De Novo Protein Design for Targeted Therapeutics","volume":"550","author":"Chevalier","year":"2017","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1006112","DOI":"10.1371\/journal.pcbi.1006112","article-title":"Rosettaantibodydesign (Rabd): A General Framework for Computational Antibody Design","volume":"14","author":"Adolf-Bryfogle","year":"2018","journal-title":"PloS Comput Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.690742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T18:37:26Z","timestamp":1672252646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.690742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2021.690742"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.690742","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"article-number":"690742"}}